Related Experiment Video
Updated: Jun 7, 2026

In utero Measurement of Heart Rate in Mouse by Noninvasive M-mode Echocardiography
Published on: November 22, 2013
Heart-specific ablation of Prkar1a causes failure of heart development and myxomagenesis
Zhirong Yin1, Georgette N Jones, William H Towns
1Department of Molecular Virology, Immunology, and Molecular Genetics, Ohio State University, Columbus, USA.
Background:
Protein kinase A signaling has long been known to play an important role in cardiac function. Dysregulation of the protein kinase A system, caused by mutation of the protein kinase A regulatory subunit gene PRKAR1A, causes the inherited tumor syndrome Carney complex, which includes cardiac myxomas as one of its cardinal features. Mouse models of this genetic defect have been unsatisfactory because homozygote null animals die early in development and heterozygotes do not exhibit a cardiac phenotype.
Methods And Results:
To study the cardiac-specific effects resulting from complete loss of Prkar1a, we used cre-lox technology to generate mice lacking this protein specifically in cardiomyocytes. Conditional knockout mice died at day 11.5 to 12.5 of embryogenesis with thin-walled, dilated hearts. These hearts showed elevated protein kinase A activity and decreased cardiomyocyte proliferation before demise. Analysis of the expression of transcription factors required for cardiogenesis revealed downregulation of key cardiac transcription factors such as the serum response factor, Gata4, and Nkx2-5. Although heart wall thickness was reduced overall, specific areas exhibited morphological changes consistent with myxomatous degeneration in the walls of knockout hearts.
Conclusions:
Loss of Prkar1a from the heart causes a failure of proper myocardial development with subsequent cardiac failure and embryonic demise. These changes appear to be due to suppression of cardiac-specific transcription by increased protein kinase A activity. These biochemical changes lead to myxoma-like changes, indicating that these mice may be a good model with which to study the formation of these tumors.
Insights
Loss of the PRKAR1A gene in heart cells causes developmental failure and embryonic death in mice. This leads to cardiac issues and myxoma-like changes, offering a new model for tumor research.
Area of Science:
- Cardiovascular Biology
- Molecular Genetics
- Developmental Biology
Background:
- Protein kinase A (PKA) signaling is crucial for cardiac function.
- Mutations in PRKAR1A cause Carney complex, characterized by cardiac myxomas.
- Existing mouse models for PRKAR1A defects have limitations in studying cardiac phenotypes.
Purpose of the Study:
- To investigate the cardiac-specific consequences of complete Prkar1a loss in cardiomyocytes.
- To develop a viable mouse model for studying PRKAR1A-related cardiac defects and tumor formation.
Main Methods:
- Utilized cre-lox technology for conditional knockout of Prkar1a in cardiomyocytes.
- Generated and analyzed conditional knockout mice during embryonic development.
- Assessed cardiac morphology, PKA activity, cardiomyocyte proliferation, and gene expression.
Main Results:
- Conditional knockout mice exhibited embryonic lethality between days 11.5-12.5 with dilated, thin-walled hearts.
- Elevated PKA activity and reduced cardiomyocyte proliferation were observed prior to embryonic demise.
- Downregulation of key cardiac transcription factors (SRF, Gata4, Nkx2-5) and myxoma-like changes in heart walls were noted.
Conclusions:
- Complete loss of Prkar1a in the heart disrupts myocardial development, leading to cardiac failure and embryonic death.
- Increased PKA activity suppresses cardiac-specific transcription, causing developmental abnormalities.
- These findings establish a valuable mouse model for studying cardiac myxoma formation.
Related Concept Videos
Pathophysiology of Heart Failure
Development of the Heart
As the embryo undergoes lateral folding, these paired tubes approach each other, merging into a single primitive heart tube by...
Rheumatic Heart Disease I: Introduction
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy

